Lucid Ultra 128 vs Otofonix Groove

The Lucid Ultra 128 is a premium behind-the-ear prescription hearing aid priced at $5,000, earning an A grade with a SoundScore of 4.4/5 in our lab testing. It ranks #17 among 39 prescription hearing aids tested, placing it in the top 41% of its category. Speech performance is where the Lucid Ultra 128 truly excels. In our lab testing, speech in quiet scored a strong 4.3/5, which is 0.95 points above the category average. Speech in noise performance reached 2.7/5, which sits above the category average by 0.59 points, though it remains mixed in absolute terms. This suggests the device handles conversational clarity well in our test scenarios, particularly in quieter environments. The device does face some challenges. Feedback handling scored just 1.7/5, falling 3.02 points below the category average of 4.72/5—a notable weakness compared to other prescription aids in our testing. Music streaming also came in below average at 2.3/5, which is 0.46 points under the category norm. Own-voice comfort scored a mixed 2.9/5, slightly above average. At this price point, several competitors in our database achieved higher overall scores, including the Phonak Sphere Infinio and Oticon Intent. The Lucid Ultra 128 features disposable batteries and supports both iPhone and Android streaming. It may appeal to users who prioritize speech clarity in quiet settings and are less concerned about feedback stability or music streaming fidelity in our standardized tests.

The Otofonix Groove is a behind-the-ear prescription hearing aid priced at $795, earning a C grade with a SoundScore of 2.7/5 in our lab testing. This rechargeable BTE ranks #38 of 39 devices in the prescription hearing aid category, placing it in the bottom 5% of its class. In our testing, the Groove demonstrated excellent feedback handling at 5.0/5, scoring 0.28 points above the category average. This represents a genuine strength, with the device maintaining stability during our standardized challenge motions. However, speech performance was significantly limited, with speech in quiet scoring 1.0/5 (2.40 points below the category average of 3.40) and speech in noise also at 1.0/5 (1.11 points below average). Music streaming was not functional in our tests, scoring 0.0/5 against a category average of 2.76. Own-voice comfort also fell well below typical prescription hearing aid performance at 0.4/5, which is 2.30 points below the category average. At this price point, several lower-cost alternatives delivered stronger overall performance in our testing. Consumers seeking value in the prescription category may want to explore other options, though those requiring robust feedback control in a rechargeable BTE format may find the Groove's stability noteworthy despite its other limitations.